Can GSK Market Breo Ellipta Dosing Advantage Without Adherence Advantage?
After successful advisory panel – at least for adult asthma indication – Breo Ellipta seems headed for an expanded label, but GSK is still struggling to find some clinical differentiation from its aging twice-daily Advair.
You may also be interested in...
Should using adult data to label a product for kids be ‘a judgment call?’ Advisory committee asks whether FDA needs more explicit criteria during review of GSK’s Breo Ellipta.
Follow-on may continue to face adoption challenges with expanded indication despite dosing convenience.
The Trump administration says a COVID-19 vaccine could be available in as little as 12 months, but most experts think that is overpromising unless safety or efficacy standards are sacrificed. Many are urging pivotal studies that look at clinical outcomes, not surrogates, for US FDA approval.